Compare Stocks: ARVN, BHVN, PVLA, and ZBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.99 +2.7%	$8.06	$6.32 ▼ $14.51	$564.56M	1.71	899,065 shs	671,639 shs
BHVN Biohaven	$14.58 -0.5%	$14.02	$7.48 ▼ $18.57	$2.21B	1.26	1.82 million shs	1.38 million shs
PVLA Palvella Therapeutics	$152.22 -3.5%	$134.55	$40.22 ▼ $161.38	$2.27B	-0.17	210,317 shs	140,007 shs
ZBIO Zenas BioPharma	$31.99 -1.4%	$25.91	$13.50 ▼ $44.60	$2.05B	-1.03	718,339 shs	409,915 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+8.97%	+5.80%	-9.42%	+39.11%
BHVN Biohaven	0.00%	+8.72%	-5.94%	+61.97%	-0.34%
PVLA Palvella Therapeutics	0.00%	+13.47%	+8.99%	+29.22%	+285.75%
ZBIO Zenas BioPharma	0.00%	+3.15%	+12.84%	+58.97%	+121.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.99 +2.7%	$8.06	$6.32 ▼ $14.51	$564.56M	1.71	899,065 shs	671,639 shs
BHVN Biohaven	$14.58 -0.5%	$14.02	$7.48 ▼ $18.57	$2.21B	1.26	1.82 million shs	1.38 million shs
PVLA Palvella Therapeutics	$152.22 -3.5%	$134.55	$40.22 ▼ $161.38	$2.27B	-0.17	210,317 shs	140,007 shs
ZBIO Zenas BioPharma	$31.99 -1.4%	$25.91	$13.50 ▼ $44.60	$2.05B	-1.03	718,339 shs	409,915 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+8.97%	+5.80%	-9.42%	+39.11%
BHVN Biohaven	0.00%	+8.72%	-5.94%	+61.97%	-0.34%
PVLA Palvella Therapeutics	0.00%	+13.47%	+8.99%	+29.22%	+285.75%
ZBIO Zenas BioPharma	0.00%	+3.15%	+12.84%	+58.97%	+121.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.45	Hold	$14.17	57.58% Upside
BHVN Biohaven	2.67	Moderate Buy	$21.63	48.32% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	37.40% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$44.29	38.44% Upside

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, PVLA, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/10/2026	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $21.00
8/5/2026	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$207.00
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00
8/5/2026	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$232.00
8/5/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$15.00 ➝ $11.00
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
8/4/2026	ARVN Arvinas	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
7/30/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	2.21	N/A	N/A	$6.76 per share	1.33
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
PVLA Palvella Therapeutics	$42.81M	51.24	N/A	N/A	$2.36 per share	64.50
ZBIO Zenas BioPharma	$10M	201.95	N/A	N/A	$4.51 per share	7.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	89.91	N/A	N/A	2.94%	1.91%	1.29%	N/A
BHVN Biohaven	-$738.82M	-$5.67	N/A	N/A	N/A	N/A	-866.46%	-137.99%	8/10/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	N/A
ZBIO Zenas BioPharma	-$377.74M	-$8.47	N/A	N/A	N/A	N/A	-99.99%	-58.06%	8/11/2026 (Estimated)

Latest ARVN, BHVN, PVLA, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	N/A	N/A	N/A	$15.00 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.78	-$0.0190	-$0.91	$0.49 million	N/A
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
5/13/2026	Q1 2026	ZBIO Zenas BioPharma	-$1.4742	-$1.46	+$0.0142	-$1.46	$25.00 million	N/A
5/11/2026	Q1 2026	ARVN Arvinas	-$0.95	-$0.90	+$0.05	-$0.90	$16.61 million	$15.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
BHVN Biohaven	1.87	7.41	7.41
PVLA Palvella Therapeutics	N/A	21.18	21.18
ZBIO Zenas BioPharma	1.04	11.94	11.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BHVN Biohaven	88.78%
PVLA Palvella Therapeutics	40.11%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
BHVN Biohaven	13.80%
PVLA Palvella Therapeutics	17.20%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
BHVN Biohaven	239	150.56 million	129.78 million	Optionable
PVLA Palvella Therapeutics	N/A	14.41 million	11.93 million	N/A
ZBIO Zenas BioPharma	N/A	63.13 million	49.24 million	N/A

ARVN, BHVN, PVLA, and ZBIO Headlines

Recent News About These Companies

Zenas BioPharma (ZBIO) Expected to Post Quarterly Earnings on Tuesday

August 9 at 3:56 AM | americanbankingnews.com

Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Target Price at $44.29

August 3, 2026 | americanbankingnews.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts

July 29, 2026 | marketbeat.com

Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

July 28, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC

July 24, 2026 | marketbeat.com

SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO

July 24, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO

July 22, 2026 | marketbeat.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?

July 17, 2026 | marketbeat.com

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

July 14, 2026 | seekingalpha.com

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

July 11, 2026 | finance.yahoo.com

Zenas BioPharma Inc ZBIO

June 27, 2026 | morningstar.comM

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

June 24, 2026 | theglobeandmail.com

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

June 21, 2026 | fool.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2026 | globenewswire.com

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

June 11, 2026 | globenewswire.com

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...

June 2, 2026 | finance.yahoo.com

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

June 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, PVLA, and ZBIO Company Descriptions

Arvinas NASDAQ:ARVN

$8.99 +0.24 (+2.74%)

As of 04:00 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Biohaven NYSE:BHVN

$14.58 -0.08 (-0.55%)

As of 03:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Palvella Therapeutics NASDAQ:PVLA

$152.22 -5.55 (-3.52%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Zenas BioPharma NASDAQ:ZBIO

$31.99 -0.44 (-1.36%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, PVLA, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, BHVN, PVLA, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, BHVN, PVLA, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, PVLA, and ZBIO Company Descriptions

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Palvella Therapeutics NASDAQ:PVLA

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, PVLA, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, BHVN, PVLA, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, BHVN, PVLA, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, PVLA, and ZBIO Company Descriptions

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Palvella Therapeutics NASDAQ:PVLA

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools